インフルエンザワクチンの世界市場2020-2030

【英語タイトル】Influenza Vaccines Market Report 2020-2030

visiongainが出版した調査資料(VGA20DE003)・商品コード:VGA20DE003
・発行会社(調査会社):visiongain
・発行日:2020年10月
・ページ数:285
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)USD5,850 ⇒換算¥608,400見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,099 ⇒換算¥946,296見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The emergence of a Universal Flu Vaccine
The influenza vaccine market is constantly thriving to improve vaccine efficiency and provide better protection each season. Is this possible? Pharma companies tackle novel approaches to vaccine technology, better administration and delivery, plus production of the vaccine. Never has this been more critical – yet never before has it offered you such opportunity for development.

Forecasts to 2030 and other analyses reveal the commercial prospects

In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares of your main competitors.
Original analyses – this is not available anywhere else
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, product profiles and commercial developments.
UNIQUE COVID-19 VARIATIONS – only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop – no matter how COVID-19 effects the economy.

Discover sales predictions for the world market and submarkets

By Vaccine Type
Quadrivalent
Trivalent
By End-Users
Hospitals
Specialty Clinics
Other End-Users
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 14 leading national markets:

By Region
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.

【レポートの目次】

1. Report Overview
1.1. Global Influenza Vaccines Market Segmentation
1.1 Why You Should Read This Report
1.2 What This Report Delivers
1.3 Key Questions Answered By This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQs)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2 Introduction
2.1 What is Influenza
2.2 Bird Flu
2.2.1 The avian influenza virus causes bird flu. Birds can be infected by influenza A viruses and all of its subtypes.
2.3 Annual Epidemics
2.3.1 Every year influenza causes 3-5 million cases of severe illness
2.4 Social & Economic Burden
2.4.1 An estimated $17 billion in the US alone is spent on direct medical costs and loss of labor on adults who have contracted influenza
3 Influenza Vaccine by Technology
3.1 Egg Based Flu Vaccine
3.1.1 The egg-based production system is used to make almost 500 million doses of flu vaccine every year.
3.2 Cell-Based Flu Vaccines
3.2.1 FDA issued an approval for Seqirus, the sole FDA-approved cell-based flu vaccine manufacturer in the United States, to use cell-grown CVVs.
3.3 Recombinant Flu Vaccines
3.3.1 This process can produce vaccine in the shortest amount of time
4 Executive Summary
4.1 Trivalent vaccine type anticipated to hold ~US$ 3.6 billion revenue in 2020
4.2 Quadrivalent to witness a CAGR of over 8%
4.3 Asia Pacific to witness the highest CAGR of over ~6%
5 Global Influenza Vaccines Market Overview
5.1 Drivers
5.1.1 Growing Elderly Population: Influenza vaccinations account for 50% of the demand for elderly people over 65 years
5.1.2 Growing Investments in Vaccine Development: Strong impetus for vaccine manufacturers to renew and/or expand research efforts
5.1.3 High Prevalence of Infectious Diseases: High prevalence of diseases, such as cholera, tuberculosis, hepatitis, and malaria will ensure strong demand for associated vaccines
5.1.4 Rising R&D Activities: Rising prevalence of infectious diseases and the growing focus on the immunization programs are considered as the major factors that are projected to enhance the growth
5.1.5 Increase in Government Focus on Immunization Programs: Broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs
5.1.6 Paediatric Influenza Vaccines: Paediatric influenza vaccines make up the second largest share of this vaccine industry
5.2 Restraints
5.2.1 Inadequate Reimbursement Coverage: National Immunization Survey found that 79% of privately insured children had some sort of payment associated with their last immunization visit.
5.2.2 Longer timelines required for Vaccine Production: Vaccine development is a long, complex process, often lasting 10-15 years
5.3 Opportunities
5.3.1 Rising Demand from Emerging Economies: China and India have already implemented the influenza vaccine into their immunization programmes
5.4 Market Trends
5.4.1 Demand Driven Trends: Developing economies are increasingly looking to improve their healthcare systems
5.4.2 Funding Trends: Despite the trend of increasing demand and supply in the future for the influenza vaccines market, funding is another factor that will affect the growth of the market
5.4.3 Protecting Workforce: Influenza results in hospitalization of up to 200,000 people each year. Such healthcare costs and burden have forced the governments to recognize the severity of influenza as a serious infection
5.5 SWOT Analysis
5.5.1 Strengths
5.5.1.1 Ageing Population
5.5.1.2 Influenza Prevention is Crucial
5.5.1.3 Growing Emerging Economies
5.5.1.4 Rising Disease Awareness
5.5.2 Weaknesses
5.5.2.1 Supply Chain Costs
5.5.2.2 Time Constraints
5.5.2.3 Barriers to Entry
5.5.2.4 Storage and Handling of Influenza Vaccines
5.5.3 Opportunities
5.5.3.1 Strong R&D Pipeline
5.5.3.2 Innovations and Technological Advancements
5.5.3.3 Universal Flu Vaccine
5.5.3.4 Adult Vaccines
5.5.4 Threats
5.5.4.1 Productivity Gap
5.6 PEST Analysis
5.6.1 Political Factors
5.6.1.1 Influence of Governments: The economic issues are very closely linked to the political issues that could influence the influenza vaccines market
5.6.2 Economic Factors
5.6.2.1 Cost & Time: Cost is a big factor in most things, and the influenza vaccines industry is no exception
5.6.2.2 Emerging Economies: High needs for preventive medicine across emerging economies to boost market growth
5.6.3 Social Factors
5.6.3.1 Creating a Healthier Society: One of the biggest social factors of the influenza vaccines industry would be the obvious benefits to healthcare that they bring
5.6.3.2 Public Fears of Side-Effects: On the flip side of the health benefits that vaccines bring, we can see slight resistance to vaccines from some
5.6.4 Technological Factors
5.6.4.1 Advancements in Vaccine Technology: Advancements being made in the influenza vaccine development will play a part in the future of the business
5.7 R&D Landscape Analysis
5.7.1 Fluzone® QIV HD: Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.
5.7.2 AFLURIA® Quad (Quadrivalent Egg-based Influenza Vaccine): Afluria Quad™ is an inactivated quadrivalent influenza vaccine indicated for use in adults aged 18 years and over.
5.7.3 FLUCELVAX®: FLUCELVAX QUADRIVALENT is approved for use in persons 4 years of age and older.
5.7.4 FLUAD®: FLUAD is approved in over 30 countries; and to date, more than 81 million FLUAD doses have been distributed worldwide.
5.7.5 UNI-FLU: This candidate is a nanoparticle vaccine that self-assembles during production and that displays a cross-reactive antigen for each broad influenza group
5.7.6 NanoFlu™
6 Market Comparison Developed V.S. Emerging Economies
6.1 Developed Economies
6.2 Emerging Economies
6.3 Influenza Vaccine Situation Across LMIC Region
6.3.1 Egypt: Vaccination coverage remains low in Egypt
6.3.2 Lebanon: Uptake of the vaccines is improving; it is still a long way to achieve full coverage of high-risk vaccines.
6.3.3 Saudi Arabia: There have also been several public awareness campaigns the flu vaccine is administered and funded by MoH.
7 Global Influenza Vaccines Market Size Forecast 2020-2030 by Vaccine Type
7.1 Global Influenza Vaccines Market for Quadrivalent Segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
7.1.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Quadrivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
7.1.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Quadrivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
7.1.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Quadrivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
7.1.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Quadrivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
7.2 Global Influenza Vaccines Market for Trivalent Segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
7.2.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Trivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
7.2.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Trivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
7.2.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Trivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
7.2.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Trivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8 Global Influenza Vaccines Market Size Forecast 2020-2030 by End-Users
8.1 Global Influenza Vaccines Market for Hospitals Segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.1.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Hospitals Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.1.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Hospitals Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.1.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Hospitals Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.1.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Hospitals Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.2 Global Influenza Vaccines Market for Specialty clinics segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.2.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Specialty Clinics Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.2.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Specialty Clinics Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.2.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Specialty Clinics Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.2.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Specialty Clinics Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.3 Global Influenza Vaccines Market for Other End-Users Segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.3.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Other End-Users Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.3.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Other End-Users Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.3.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Other End-Users Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
8.3.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Other End-Users Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
9 Regional and Leading National Influenza Vaccines Market Forecasts 2020-2030
9.1 Global Influenza Vaccines Market by National Market Forecast 2020-2030
9.1.1 “V” Shaped Recovery: Global Influenza Vaccines Market Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
9.1.2 “U” Shaped Recovery: Global Influenza Vaccines Market Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
9.1.3 “W” Shaped Recovery: Global Influenza Vaccines Market Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
9.1.4 “L” Shaped Recovery: Global Influenza Vaccines Market Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
10 North America
10.1 North America Influenza Vaccines Market by Country Forecast 2020-2030
10.2 North America Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
10.2.1 Recovery Scenarios (V, U, W, L): North America Influenza Vaccines Market by Vaccine Type
10.3 North America Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
10.3.1 Recovery Scenarios (V, U, W, L): North America Influenza Vaccines Market by End-Users
10.4 U.S. Influenza Vaccines Market Forecast 2020-2030
10.4.1 Obama Healthcare Reform – the Benefits for Vaccine Sales
10.4.2 In the US Influenza Vaccines Come Equally from Manufacturers and Distributors
10.4.3 “V” Shaped Recovery Scenario: U.S. Influenza Vaccines Market Forecast 2020-2030
10.4.4 “U” Shaped Recovery Scenario: U.S. Influenza Vaccines Market Forecast 2020-2030
10.4.5 “W” Shaped Recovery Scenario: U.S. Influenza Vaccines Market Forecast 2020-2030
10.4.6 “L” Shaped Recovery Scenario: U.S. Influenza Vaccines Market Forecast 2020-2030
10.5 Canada Influenza Vaccines Market Forecast 2020-2030
10.5.1 High Burden Among Children Population
10.5.2 Vaccine Products Available for Use in Canada
10.5.3 “V” Shaped Recovery Scenario: Canada Influenza Vaccines Market Forecast 2020-2030
10.5.4 “U” Shaped Recovery Scenario: Canada Influenza Vaccines Market Forecast 2020-2030
10.5.5 “W” Shaped Recovery Scenario: Canada Influenza Vaccines Market Forecast 2020-2030
10.5.6 “L” Shaped Recovery Scenario: Canada Influenza Vaccines Market Forecast 2020-2030
11 Europe
11.1 Europe Influenza Vaccines Market by Country Forecast 2020-2030
11.2 Europe Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
11.2.1 Recovery Scenarios (V, U, W, L): Europe Influenza Vaccines Market by Vaccine Type
11.3 Europe Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
11.3.1 Recovery Scenarios (V, U, W, L): Europe Influenza Vaccines Market by End-Users
11.4 Germany Influenza Vaccines Market Forecast 2020-2030
11.4.1 Economic Downturn and Ripple Effect
11.4.2 “V” Shaped Recovery Scenario: Germany Influenza Vaccines Market Forecast 2020-2030
11.4.3 “U” Shaped Recovery Scenario: Germany Influenza Vaccines Market Forecast 2020-2030
11.4.4 “W” Shaped Recovery Scenario: Germany Influenza Vaccines Market Forecast 2020-2030
11.4.5 “L” Shaped Recovery Scenario: Germany Influenza Vaccines Market Forecast 2020-2030
11.5 France Influenza Vaccines Market Forecast 2020-2030
11.5.1 Prominent Market
11.5.2 French Healthcare System
11.5.3 Doubt over Vaccine Safety Among French Population
11.5.4 “V” Shaped Recovery Scenario: France Influenza Vaccines Market Forecast 2020-2030
11.5.5 “U” Shaped Recovery Scenario: France Influenza Vaccines Market Forecast 2020-2030
11.5.6 “W” Shaped Recovery Scenario: France Influenza Vaccines Market Forecast 2020-2030
11.5.7 “L” Shaped Recovery Scenario: France Influenza Vaccines Market Forecast 2020-2030
11.6 UK Influenza Vaccines Market Forecast 2020-2030
11.6.1 Mature Market
11.6.2 “V” Shaped Recovery Scenario: UK Influenza Vaccines Market Forecast 2020-2030
11.6.3 “U” Shaped Recovery Scenario: UK Influenza Vaccines Market Forecast 2020-2030
11.6.4 “W” Shaped Recovery Scenario: UK Influenza Vaccines Market Forecast 2020-2030
11.6.5 “L” Shaped Recovery Scenario: UK Influenza Vaccines Market Forecast 2020-2030
11.7 Italy Influenza Vaccines Market Forecast 2020-2030
11.7.1 Economic Climate
11.7.2 Challenges in Public Healthcare
11.7.3 “V” Shaped Recovery Scenario: Italy Influenza Vaccines Market Forecast 2020-2030
11.7.4 “U” Shaped Recovery Scenario: Italy Influenza Vaccines Market Forecast 2020-2030
11.7.5 “W” Shaped Recovery Scenario: Italy Influenza Vaccines Market Forecast 2020-2030
11.7.6 “L” Shaped Recovery Scenario: Italy Influenza Vaccines Market Forecast 2020-2030
11.8 Spain Influenza Vaccines Market Forecast 2020-2030
11.8.1 Ageing Population
11.8.2 Economic Challenges
11.8.3 “V” Shaped Recovery Scenario: Spain Influenza Vaccines Market Forecast 2020-2030
11.8.4 “U” Shaped Recovery Scenario: Spain Influenza Vaccines Market Forecast 2020-2030
11.8.5 “W” Shaped Recovery Scenario: Spain Influenza Vaccines Market Forecast 2020-2030
11.8.6 “L” Shaped Recovery Scenario: Spain Influenza Vaccines Market Forecast 2020-2030
11.9 Rest of Europe Influenza Vaccines Market Forecast 2020-2030
11.9.1 “V” Shaped Recovery Scenario: Rest of Europe Influenza Vaccines Market Forecast 2020-2030
11.9.2 “U” Shaped Recovery Scenario: Rest of Europe Influenza Vaccines Market Forecast 2020-2030
11.9.3 “W” Shaped Recovery Scenario: Rest of Europe Influenza Vaccines Market Forecast 2020-2030
11.9.4 “L” Shaped Recovery Scenario: Rest of Europe Influenza Vaccines Market Forecast 2020-2030
12 Asia Pacific
12.1 Asia Pacific Influenza Vaccines Market by Country Forecast 2020-2030
12.2 Asia Pacific Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
12.2.1 Recovery Scenarios (V, U, W, L): Asia Pacific Influenza Vaccines Market by Vaccine Type
12.3 Asia Pacific Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
12.3.1 Recovery Scenarios (V, U, W, L): Asia Pacific Influenza Vaccines Market by End-Users
12.4 Japan Influenza Vaccines Market Forecast 2020-2030
12.4.1 Challenging Market
12.4.2 Vaccine Gap to Offer Immense Growth Opportunities
12.4.3 “V” Shaped Recovery Scenario: Japan Influenza Vaccines Market Forecast 2020-2030
12.4.4 “U” Shaped Recovery Scenario: Japan Influenza Vaccines Market Forecast 2020-2030
12.4.5 “W” Shaped Recovery Scenario: Japan Influenza Vaccines Market Forecast 2020-2030
12.4.6 “L” Shaped Recovery Scenario: Japan Influenza Vaccines Market Forecast 2020-2030
12.5 China Influenza Vaccines Market Forecast 2020-2030
12.5.1 Growing Population
12.5.2 Growing National Demand
12.5.3 Low Confidence Towards Domestic Vaccine
12.5.4 Voluntarily Spending by Chinese Population
12.5.5 “V” Shaped Recovery Scenario: China Influenza Vaccines Market Forecast 2020-2030
12.5.6 “U” Shaped Recovery Scenario: China Influenza Vaccines Market Forecast 2020-2030
12.5.7 “W” Shaped Recovery Scenario: China Influenza Vaccines Market Forecast 2020-2030
12.5.8 “L” Shaped Recovery Scenario: China Influenza Vaccines Market Forecast 2020-2030
12.6 India Influenza Vaccines Market Forecast 2020-2030
12.6.1 Emerging Market
12.6.2 “V” Shaped Recovery Scenario: India Influenza Vaccines Market Forecast 2020-2030
12.6.3 “U” Shaped Recovery Scenario: India Influenza Vaccines Market Forecast 2020-2030
12.6.4 “W” Shaped Recovery Scenario: India Influenza Vaccines Market Forecast 2020-2030
12.6.5 “L” Shaped Recovery Scenario: India Influenza Vaccines Market Forecast 2020-2030
12.7 Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
12.7.1 “V” Shaped Recovery Scenario: Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
12.7.2 “U” Shaped Recovery Scenario: Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
12.7.3 “W” Shaped Recovery Scenario: Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
12.7.4 “L” Shaped Recovery Scenario: Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
13 Latin America
13.1 Latin America Influenza Vaccines Market by Country Forecast 2020-2030
13.2 Latin America Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
13.2.1 Recovery Scenarios (V, U, W, L): Latin America Influenza Vaccines Market by Vaccine Type
13.3 Latin America Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
13.3.1 Recovery Scenarios (V, U, W, L): Latin America Influenza Vaccines Market by End-Users
13.4 Brazil Influenza Vaccines Market Forecast 2020-2030
13.4.1 “V” Shaped Recovery Scenario: Brazil Influenza Vaccines Market Forecast 2020-2030
13.4.2 “U” Shaped Recovery Scenario: Brazil Influenza Vaccines Market Forecast 2020-2030
13.4.3 “W” Shaped Recovery Scenario: Brazil Influenza Vaccines Market Forecast 2020-2030
13.4.4 “L” Shaped Recovery Scenario: Brazil Influenza Vaccines Market Forecast 2020-2030
13.5 Mexico Influenza Vaccines Market Forecast 2020-2030
13.5.1 “V” Shaped Recovery Scenario: Mexico Influenza Vaccines Market Forecast 2020-2030
13.5.2 “U” Shaped Recovery Scenario: Mexico Influenza Vaccines Market Forecast 2020-2030
13.5.3 “W” Shaped Recovery Scenario: Mexico Influenza Vaccines Market Forecast 2020-2030
13.5.4 “L” Shaped Recovery Scenario: Mexico Influenza Vaccines Market Forecast 2020-2030
13.6 Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
13.6.1 “V” Shaped Recovery Scenario: Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
13.6.2 “U” Shaped Recovery Scenario: Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
13.6.3 “W” Shaped Recovery Scenario: Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
13.6.4 “L” Shaped Recovery Scenario: Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
14 Middle East and Africa
14.1 Middle East and Africa Influenza Vaccines Market by Country Forecast 2020-2030
14.2 Middle East and Africa Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
14.2.1 Recovery Scenarios (V, U, W, L): Middle East and Africa Influenza Vaccines Market by Vaccine Type
14.3 Middle East and Africa Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
14.3.1 Recovery Scenarios (V, U, W, L): Middle East and Africa Influenza Vaccines Market by End-Users
14.4 GCC Influenza Vaccines Market Forecast 2020-2030
14.4.1 “V” Shaped Recovery Scenario: GCC Influenza Vaccines Market Forecast 2020-2030
14.4.2 “U” Shaped Recovery Scenario: GCC Influenza Vaccines Market Forecast 2020-2030
14.4.3 “W” Shaped Recovery Scenario: GCC Influenza Vaccines Market Forecast 2020-2030
14.4.4 “L” Shaped Recovery Scenario: GCC Influenza Vaccines Market Forecast 2020-2030
14.5 South Africa Influenza Vaccines Market Forecast 2020-2030
14.5.1 “V” Shaped Recovery Scenario: South Africa Influenza Vaccines Market Forecast 2020-2030
14.5.2 “U” Shaped Recovery Scenario: South Africa Influenza Vaccines Market Forecast 2020-2030
14.5.3 “W” Shaped Recovery Scenario: South Africa Influenza Vaccines Market Forecast 2020-2030
14.5.4 “L” Shaped Recovery Scenario: South Africa Influenza Vaccines Market Forecast 2020-2030
14.6 Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
14.6.1 “V” Shaped Recovery Scenario: Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
14.6.2 “U” Shaped Recovery Scenario: Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
14.6.3 “W” Shaped Recovery Scenario: Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
14.6.4 “L” Shaped Recovery Scenario: Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
15 Company Profiling
15.1 Biodiem
15.1.1 Biodiem: Company Snapshot
15.1.2 Biodiem: Company Overview
15.1.3 Biodiem: Financial Analysis
15.1.3.1 Net Revenue, 2015-2019
15.1.4 Biodiem: Products
15.1.5 Biodiem: Recent Developments
15.2 CSL Limited
15.2.1 CSL Limited: Company Snapshot
15.2.2 CSL Limited: Company Overview
15.2.3 CSL Limited: Financial Analysis
15.2.3.1 Net Revenue, 2015-2019
15.2.3.2 Gross Profit, 2015-2019
15.2.4 CSL Limited: Products
15.2.5 CSL Limited: Recent Developments
15.3 Emergent BioSolutions
15.3.1 Emergent BioSolutions: Company Snapshot
15.3.2 Emergent BioSolutions: Company Overview
15.3.3 Emergent BioSolutions: Financial Analysis
15.3.3.1 Net Revenue, 2015-2019
15.3.3.2 EBIDTA, 2015-2019
15.3.3.3 Gross Profit, 2015-2019
15.3.4 Emergent BioSolutions: Products
15.3.5 Emergent BioSolutions: Recent Developments
15.4 AstraZeneca
15.4.1 AstraZeneca: Company Snapshot
15.4.2 AstraZeneca: Company Overview
15.4.3 AstraZeneca: Financial Analysis
15.4.3.1 Net Revenue, 2015-2019
15.4.3.2 EBIDTA, 2015-2019
15.4.3.3 Gross Profit, 2015-2019
15.5 Merck & Co., Inc.
15.5.1 Merck & Co., Inc.: Company Snapshot
15.5.2 Merck & Co., Inc.: Company Overview
15.5.3 Merck & Co., Inc.: Financial Analysis
15.5.3.1 Net Revenue, 2015-2019
15.5.3.2 EBIDTA, 2015-2019
15.5.3.3 Gross Profit, 2015-2019
15.5.4 Merck & Co., Inc.: Recent Developments
15.6 Sanofi
15.6.1 Sanofi: Company Snapshot
15.6.2 Sanofi: Company Overview
15.6.3 Sanofi: Financial Analysis
15.6.3.1 Net Revenue, 2015-2019
15.6.3.2 EBIDTA, 2015-2019
15.6.3.3 Gross Profit, 2015-2019
15.6.4 Sanofi: Products
15.6.5 Sanofi: Recent Developments
15.7 F. Hoffmann-La Roche Ltd.
15.7.1 F. Hoffmann-La Roche Ltd.: Company Snapshot
15.7.2 F. Hoffmann-La Roche Ltd.: Company Overview
15.7.3 F. Hoffmann-La Roche Ltd.: Financial Analysis
15.7.3.1 Net Revenue, 2015-2019
15.7.3.2 EBIDTA, 2015-2019
15.7.3.3 Gross Profit, 2015-2019
15.7.4 F. Hoffmann-La Roche Ltd.: Recent Developments
15.8 Sinovac Biotech Ltd.
15.8.1 Sinovac Biotech Ltd.: Company Snapshot
15.8.2 Sinovac Biotech Ltd.: Company Overview
15.8.3 Sinovac Biotech Ltd.: Financial Analysis
15.8.3.1 Net Revenue, 2015-2019
15.8.3.2 EBIDTA, 2015-2019
15.8.3.3 Gross Profit, 2015-2019
15.8.4 Sinovac Biotech Ltd.: Recent Developments
15.9 Mitsubishi Tanabe Pharma Corporation
15.9.1 Mitsubishi Tanabe Pharma Corporation: Company Snapshot
15.9.2 Mitsubishi Tanabe Pharma Corporation: Company Overview
15.9.3 Mitsubishi Tanabe Pharma Corporation: Financial Analysis
15.9.3.1 Net Revenue, 2016-2018
15.9.4 Mitsubishi Tanabe Pharma Corporation: Recent Developments
15.10 Takeda Pharmaceutical Company Limited
15.10.1 Takeda Pharmaceutical Company Limited: Company Snapshot
15.10.2 Takeda Pharmaceutical Company Limited: Company Overview
15.10.3 Takeda Pharmaceutical Company Limited: Financial Analysis
15.10.3.1 Net Revenue, 2015-2019
15.10.3.2 EBIDTA, 2015-2019
15.10.3.3 Gross Profit, 2015-2019
16 Conclusion & Recommendations
16.1 Concluding Remarks
16.2 Prevention of Influenza by Use of Flu Shots Rises in Importance
16.3 Emergence of a Universal Flu Vaccine
16.4 Unique & Complex Market
16.5 Unmet Needs & Required Innovations

List of Tables
Table 1 Global Influenza Vaccines Market Snapshot, 2020 & 2030 (US$ million, CAGR %)
Table 2 Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 3 “V” Shaped Recovery: Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 4 “U” Shaped Recovery: Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 5 “W” Shaped Recovery: Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 6 “L” Shaped Recovery: Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 7 Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 8 “V” Shaped Recovery: Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 9 “U” Shaped Recovery: Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 10 “W” Shaped Recovery: Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 11 “L” Shaped Recovery: Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 12 Global Influenza Vaccines Market by End-Users Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 13 Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 14 “V” Shaped Recovery: Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 15 “U” Shaped Recovery: Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 16 “W” Shaped Recovery: Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Table 17 “L” Shaped Recovery: Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)



★調査レポート[インフルエンザワクチンの世界市場2020-2030] (コード:VGA20DE003)販売に関する免責事項を必ずご確認ください。
★調査レポート[インフルエンザワクチンの世界市場2020-2030]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆